ENXTPA:NANOBiotechs
Is It Too Late To Consider Nanobiotix (ENXTPA:NANO) After Its 7x One Year Surge?
If you are wondering whether Nanobiotix is priced attractively or already running ahead of itself, the recent share performance raises some important valuation questions.
The stock last closed at €27.40, with a 3.4% gain over 7 days, a 5.0% decline over 30 days, a 44.2% return year to date, and a very large 1-year return of more than 7x.
These moves have kept Nanobiotix on many investors' watchlists, supported by ongoing attention on its cancer treatment technologies and partnerships in the...